Cougar Biotechnology

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Cougar Biotechnology sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 8 completed early-phase tilt top decile by trial count

Cougar Biotechnology: 9 sponsored US clinical trials, none currently recruiting.

Cougar Biotechnology sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostatic Neoplasms, with 1 trials.

Top-decile sponsor footprint

Cougar Biotechnology ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 1

A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT01400555
COMPLETED Phase 2

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

NCT01088529
COMPLETED Phase 1

A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function

NCT01715259
COMPLETED Phase 1

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

NCT02001571
COMPLETED Phase 3

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

NCT00638690
TERMINATED Phase 1

A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma

NCT00912899
COMPLETED Phase 1

A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer

NCT00600535
COMPLETED Phase 2

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

NCT00485303
COMPLETED Phase 2

An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

NCT00474383

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 3
Phase 3 1

Therapeutic Areas

Prostatic Neoplasms 1
Renal Insufficiency 1

How the Cougar Biotechnology early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 8 completed (89%).

Phase mix: 1 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Prostatic Neoplasms (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Cougar Biotechnology: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Cougar Biotechnology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Cougar Biotechnology4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Cougar Biotechnology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cougar Biotechnology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cougar Biotechnology page

9 registered trials is a research-attention snapshot, not an endorsement of Cougar Biotechnology or any single study.

  • None of Cougar Biotechnology's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Prostatic Neoplasms is the condition Cougar Biotechnology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostatic Neoplasms trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Cougar Biotechnology pipeline card: 9 registered trials from official public datasets.Report a data error.